EP1638566A4 - SULFONAMIDE-SUBSTITUTED IMIDAZOCHINOLINE - Google Patents

SULFONAMIDE-SUBSTITUTED IMIDAZOCHINOLINE

Info

Publication number
EP1638566A4
EP1638566A4 EP04756208A EP04756208A EP1638566A4 EP 1638566 A4 EP1638566 A4 EP 1638566A4 EP 04756208 A EP04756208 A EP 04756208A EP 04756208 A EP04756208 A EP 04756208A EP 1638566 A4 EP1638566 A4 EP 1638566A4
Authority
EP
European Patent Office
Prior art keywords
sulfonamide substituted
substituted imidazoquinolines
imidazoquinolines
sulfonamide
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04756208A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1638566A2 (en
Inventor
George W Griesgraber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coley Pharmaceutical Group Inc
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Publication of EP1638566A2 publication Critical patent/EP1638566A2/en
Publication of EP1638566A4 publication Critical patent/EP1638566A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP04756208A 2003-06-27 2004-06-25 SULFONAMIDE-SUBSTITUTED IMIDAZOCHINOLINE Withdrawn EP1638566A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48320003P 2003-06-27 2003-06-27
PCT/US2004/020607 WO2005003065A2 (en) 2003-06-27 2004-06-25 Sulfonamide substituted imidazoquinolines

Publications (2)

Publication Number Publication Date
EP1638566A2 EP1638566A2 (en) 2006-03-29
EP1638566A4 true EP1638566A4 (en) 2009-03-25

Family

ID=33563911

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04756208A Withdrawn EP1638566A4 (en) 2003-06-27 2004-06-25 SULFONAMIDE-SUBSTITUTED IMIDAZOCHINOLINE

Country Status (16)

Country Link
EP (1) EP1638566A4 (zh)
JP (1) JP2007521280A (zh)
KR (1) KR20060035637A (zh)
CN (1) CN1812789B (zh)
AR (2) AR044922A1 (zh)
AU (1) AU2004253929A1 (zh)
BR (1) BRPI0411916A (zh)
CA (1) CA2529322A1 (zh)
IL (1) IL172427A0 (zh)
MX (1) MXPA06000144A (zh)
MY (1) MY157827A (zh)
NZ (1) NZ544330A (zh)
RU (1) RU2374246C2 (zh)
TW (2) TW200511992A (zh)
WO (2) WO2005003065A2 (zh)
ZA (1) ZA200600769B (zh)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
TW200510412A (en) 2003-08-12 2005-03-16 3M Innovative Properties Co Oxime substituted imidazo-containing compounds
US7897597B2 (en) 2003-08-27 2011-03-01 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
WO2005023190A2 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
WO2005032484A2 (en) 2003-10-03 2005-04-14 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
AU2004315876B2 (en) 2003-10-03 2011-05-26 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
CA2545825A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
CN1906193A (zh) 2003-11-14 2007-01-31 3M创新有限公司 肟取代的咪唑环化合物
SG148201A1 (en) 2003-11-25 2008-12-31 3M Innovative Properties Co Substituted imidazo ring systems and methods
US8940755B2 (en) * 2003-12-02 2015-01-27 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
WO2005066170A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
JP2007517044A (ja) 2003-12-30 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー イミダゾキノリニル、イミダゾピリジニル、およびイミダゾナフチリジニルスルホンアミド
TW200612932A (en) 2004-03-24 2006-05-01 3M Innovative Properties Co Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
JP5313502B2 (ja) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー 置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
US20080207674A1 (en) * 2004-12-30 2008-08-28 Coley Pharmaceutical Group, Inc. Immune Response Modifier Formulations And Methods
CA2592904C (en) 2004-12-30 2015-04-07 3M Innovative Properties Company Chiral fused [1,2]imidazo[4,5-c] ring compounds
CA2597092A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
AU2006212765B2 (en) 2005-02-09 2012-02-02 3M Innovative Properties Company Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
EP1846405A2 (en) 2005-02-11 2007-10-24 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
JP2008535832A (ja) 2005-04-01 2008-09-04 コーリー ファーマシューティカル グループ，インコーポレイテッド ピラゾロピリジン−１，４−ジアミン、およびそのアナログ
JP2009507856A (ja) * 2005-09-09 2009-02-26 コーリー ファーマシューティカル グループ，インコーポレイテッド Ｎ−｛２−［４−アミノ−２−（エトキシメチル）−１Ｈ−イミダゾ［４，５−ｃ］キノリン−１−イル］−１，１−ジメチルエチル｝メタンスルホンアミドのアミドおよびカルバマート誘導体ならびに方法
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
WO2007035935A1 (en) * 2005-09-23 2007-03-29 Coley Pharmaceutical Group, Inc. METHOD FOR 1H-IMIDAZO[4,5-c]PYRIDINES AND ANALOGS THEREOF
US8951528B2 (en) 2006-02-22 2015-02-10 3M Innovative Properties Company Immune response modifier conjugates
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
ES2667054T3 (es) * 2008-03-24 2018-05-09 Biontech Ag Nuevas imidazoquinolinas sustituidas
ES2617451T3 (es) 2010-08-17 2017-06-19 3M Innovative Properties Company Composiciones lipidadas de compuestos modificadores de la respuesta inmunitaria, formulaciones, y métodos
MX355623B (es) 2011-06-03 2018-04-25 3M Innovative Properties Co Hidrazino-1h-imidazoquinolin-4-aminas y conjugados elaborados a partir de las mismas.
CA2838158C (en) 2011-06-03 2019-07-16 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
MX2018003215A (es) * 2015-09-14 2018-06-08 Pfizer Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2.
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
JP7219223B2 (ja) 2017-03-10 2023-02-07 ファイザー・インク ＬＲＲＫ２阻害剤としての新規のイミダゾ［４，５－ｃ］キノリン誘導体
IL273039B2 (en) 2017-09-06 2023-10-01 BioNTech SE Transduced imidazoquinolines as TLR7 agonists
CA3086439A1 (en) 2017-12-20 2019-06-27 3M Innovative Properties Company Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
US11744874B2 (en) * 2019-12-20 2023-09-05 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076519A1 (en) * 1999-06-10 2000-12-21 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1719511T3 (da) * 2001-11-16 2009-04-14 Coley Pharm Group Inc N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methansulfonamid, en farmaceutisk sammensætning omfattende samme, og anvendelse deraf

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076519A1 (en) * 1999-06-10 2000-12-21 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines

Also Published As

Publication number Publication date
CA2529322A1 (en) 2005-01-13
CN1812789B (zh) 2010-07-14
BRPI0411916A (pt) 2006-08-15
AR044922A1 (es) 2005-10-12
TW200514784A (en) 2005-05-01
RU2374246C2 (ru) 2009-11-27
IL172427A0 (en) 2006-04-10
RU2005138915A (ru) 2006-06-27
TW200511992A (en) 2005-04-01
WO2005003064A2 (en) 2005-01-13
NZ544330A (en) 2009-06-26
EP1638566A2 (en) 2006-03-29
MY157827A (en) 2016-07-29
ZA200600769B (en) 2007-05-30
KR20060035637A (ko) 2006-04-26
JP2007521280A (ja) 2007-08-02
CN1812789A (zh) 2006-08-02
WO2005003064A3 (en) 2005-03-31
WO2005003065A2 (en) 2005-01-13
AR044923A1 (es) 2005-10-12
WO2005003065A3 (en) 2005-03-10
MXPA06000144A (es) 2006-04-07
AU2004253929A1 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
IL172427A0 (en) Sulfonamide substituted imidazoquinolines
ZA200603879B (en) Substituted indazole-O-glucosides
IL175490A0 (en) Substituted indazole-o-glucosides
EP1663113A4 (en) SUBSTITUTED SULFONAMIDES
ZA200603880B (en) Substituted indole-O-glucosides
EP1680131A4 (en) SUBSTITUTED INDOLE-O-GLUCOSIDES
HK1088602A1 (en) 2-pyridinecarboxamide derivatives
HK1088326A1 (en) Piperidine-benzenesulfonamide derivatives
HK1089443A1 (en) Imidazol-4-yl-ethynyl-pyridine derivatives
GB0317665D0 (en) Qinazoline derivatives
PT1682493E (pt) Derivados de aminoacetonitrilo
IL175189A0 (en) N-thiazol-2-yl-benzamide derivatives
TWI368482B (en) New 2-pyridinylethylbenzamide derivatives
GB0329314D0 (en) Substituted arylpyrazoles
ZA200600430B (en) Substituted spirobenzazepines
SI1706373T1 (sl) Amidoacetonitrilni derivati
GB0316128D0 (en) Novel sulfonamide compounds
GB0319793D0 (en) Pyridinylmorpholine derivatives
GB0314781D0 (en) Sureclad
TW573910U (en) Pivot
AU2003263871A8 (en) Abiogenic transition unit
TWI341309B (en) Heteroarylcarbamoylbenzene derivatives
SI1654253T1 (sl) Substituirani 3-pirolidin-indolni derivati
AU2834P (en) Baltinblus Gaura lindheimeri
GB0307514D0 (en) Double articulated rule

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060110

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20090223

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: COLEY PHARMACEUTICAL GROUP, INC.

17Q First examination report despatched

Effective date: 20090903

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: COLEY PHARMACEUTICAL GROUP, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100515